{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04858009",
            "orgStudyIdInfo": {
                "id": "18-009451"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2021-02990",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                }
            ],
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis",
            "officialTitle": "A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Pancreatic Cancer and Peritoneal Metastasis",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "hyperthermic-intraperitoneal-chemotherapy-for-the-treatment-of-pancreatic-cancer-and-peritoneal-metastasis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-04-14",
            "studyFirstSubmitQcDate": "2021-04-22",
            "studyFirstPostDateStruct": {
                "date": "2021-04-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Cornelius A. Thiels",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This phase II trial studies the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with pancreatic cancer that has spread to the internal abdominal area (peritoneal metastasis). Chemotherapy drugs, such as nab-paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. HIPEC involves \"heated\" chemotherapy that is placed directly in the abdomen through laparoscopic instruments, instead of through an intravenous injection. This study may help doctors determine how safe and effective HIPEC work in treating patient with pancreatic cancer.",
            "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To evaluate overall survival and disease-free survival outcomes for patients with pancreatic adenocarcinoma with limited low volume peritoneal metastasis or positive peritoneal cytology undergoing hyperthermic intraperitoneal chemotherapy.\n\nSECONDARY OBJECTIVE:\n\nI. To assess morbidity for patients with pancreatic adenocarcinoma with limited low volume peritoneal metastasis or positive peritoneal cytology undergoing hyperthermic intraperitoneal chemotherapy.\n\nOUTLINE:\n\nPatients undergo HIPEC with nab-paclitaxel and cisplatin over 90 minutes in the absence of disease progression or unacceptable toxicity. Patients may undergo additional HIPEC with paclitaxel and cisplatin up to 5 times. Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI) or positron emission tomography (PET) during screening.\n\nAfter completion of study treatment, patients are followed up every 6 months."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Pancreatic Carcinoma",
                "Stage IV Pancreatic Cancer AJCC v8",
                "Metastatic Malignant Neoplasm in the Peritoneum"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment (HIPEC)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients undergo HIPEC with nab-paclitaxel and cisplatin over 90 minutes in the absence of disease progression or unacceptable toxicity. Patients may undergo additional HIPEC with paclitaxel and cisplatin up to 5 times. Patients undergo CT scan, MRI or PET during screening.",
                    "interventionNames": [
                        "Drug: Cisplatin",
                        "Drug: Hyperthermic Intraperitoneal Chemotherapy",
                        "Drug: Nab-paclitaxel",
                        "Procedure: Computed Tomography",
                        "Procedure: Magnetic Resonance Imaging",
                        "Procedure: Positron Emission Tomography"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cisplatin",
                    "description": "Given via HIPEC",
                    "armGroupLabels": [
                        "Treatment (HIPEC)"
                    ],
                    "otherNames": [
                        "Abiplatin",
                        "Blastolem",
                        "Briplatin",
                        "CDDP",
                        "Cis-diammine-dichloroplatinum",
                        "Cis-diamminedichloridoplatinum",
                        "Cis-diamminedichloro Platinum (II)",
                        "Cis-diamminedichloroplatinum",
                        "Cis-dichloroammine Platinum (II)",
                        "Cis-platinous Diamine Dichloride",
                        "Cis-platinum",
                        "Cis-platinum II",
                        "Cis-platinum II Diamine Dichloride",
                        "Cismaplat",
                        "Cisplatina",
                        "Cisplatinum",
                        "Cisplatyl",
                        "Citoplatino",
                        "Citosin",
                        "Cysplatyna",
                        "DDP",
                        "Lederplatin",
                        "Metaplatin",
                        "Neoplatin",
                        "Peyrone's Chloride",
                        "Peyrone's Salt",
                        "Placis",
                        "Plastistil",
                        "Platamine",
                        "Platiblastin",
                        "Platiblastin-S",
                        "Platinex",
                        "Platinol",
                        "Platinol- AQ",
                        "Platinol-AQ",
                        "Platinol-AQ VHA Plus",
                        "Platinoxan",
                        "Platinum",
                        "Platinum Diamminodichloride",
                        "Platiran",
                        "Platistin",
                        "Platosin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Hyperthermic Intraperitoneal Chemotherapy",
                    "description": "Undergo HIPEC with mitomycin and cisplatin",
                    "armGroupLabels": [
                        "Treatment (HIPEC)"
                    ],
                    "otherNames": [
                        "HIPEC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nab-paclitaxel",
                    "description": "Given via HIPEC",
                    "armGroupLabels": [
                        "Treatment (HIPEC)"
                    ],
                    "otherNames": [
                        "ABI 007",
                        "ABI-007",
                        "Abraxane",
                        "Albumin-bound Paclitaxel",
                        "Albumin-Stabilized Nanoparticle Paclitaxel",
                        "Nanoparticle Albumin-bound Paclitaxel",
                        "Nanoparticle Paclitaxel",
                        "Paclitaxel Albumin",
                        "paclitaxel albumin-stabilized nanoparticle formulation",
                        "Paclitaxel nanoparticle albumin-bound",
                        "Protein-bound Paclitaxel"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Computed Tomography",
                    "description": "Undergo CT scan",
                    "armGroupLabels": [
                        "Treatment (HIPEC)"
                    ],
                    "otherNames": [
                        "CAT",
                        "CAT Scan",
                        "Computed Axial Tomography",
                        "computerized axial tomography",
                        "Computerized Tomography",
                        "CT",
                        "CT Scan"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Magnetic Resonance Imaging",
                    "description": "Undergo MRI",
                    "armGroupLabels": [
                        "Treatment (HIPEC)"
                    ],
                    "otherNames": [
                        "Magnetic Resonance",
                        "Magnetic Resonance Imaging Scan",
                        "Medical Imaging",
                        "Magnetic Resonance / Nuclear Magnetic Resonance",
                        "MRI",
                        "MRI Scan",
                        "Nuclear magnetic resonance imaging (NMRI)",
                        "Structural MRI (sMRI)"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Positron Emission Tomography",
                    "description": "Undergo PET scan",
                    "armGroupLabels": [
                        "Treatment (HIPEC)"
                    ],
                    "otherNames": [
                        "Medical Imaging, Positron Emission Tomography",
                        "PET",
                        "PET Scan",
                        "positron emission tomography scan",
                        "proton magnetic resonance spectroscopic imaging",
                        "PT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Overall survival",
                    "description": "Overall survival will be assessed from the date of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) to death by any cause, regardless of disease recurrence. Patterns of tumor recurrence and survival will be assessed by reviewing routine surveillance imaging. Patient may be contacted by telephone and/or videoconferencing.",
                    "timeFrame": "Up to 4 years"
                },
                {
                    "measure": "Progression-free survival",
                    "description": "Progression-free survival is will be assessed from the date of cytoreduction and HIPEC to recurrence of tumor or death. Patterns of tumor recurrence and survival will be assessed by reviewing routine surveillance imaging. Patient may be contacted by telephone and/or videoconferencing.",
                    "timeFrame": "Up to 4 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Morbidity",
                    "description": "Morbidity is the state of having a specific illness or condition. Morbidity will be measured based on hospital length of stay, readmission rate, reoperation rate, and 30-day mortality (death).",
                    "timeFrame": "30 days; up to 4 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\>= 18 but =\\< 80\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\< 2\n* Cytologic or histologic proof of adenocarcinoma of the pancreas\n* Leukocytes \\>= 3,000/uL\n* Absolute neutrophil count \\>= 1,500/uL\n* Platelets \\>= 60,000/Ul\n* Serum creatinine =\\< 1.5 mg/dL\n* Distant metastatic disease of peritoneum may be visualized on imaging:\n\n  * Positive peritoneal cytology\n  * Limited carcinomatosis on diagnostic laparoscopy or laparotomy\n  * KRASD assay positive peritoneal washings/cytology\n* Completion of preoperative systemic chemotherapy with biochemical, metabolic, and/or radiographic response defined as a reduction in the baseline CA 19-9 by \\> 50% or radiographic response as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or metabolic response on positron emission tomography (PET)-magnetic resonance imaging (MRI) defined by PET Response Criteria in Solid Tumors (PERCIST) criteria\n* Peritoneal Carcinomatosis Index (PCI) =\\< 7 and surgeons deems high likelihood for a complete cytoreduction\n\nExclusion Criteria:\n\n* Distant metastatic disease not limited to peritoneum:\n\n  * Solid organ metastases (liver, central nervous system, lung)\n* Infections such as pneumonia or wound infections that would preclude protocol therapy\n* Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence\n* Subjects deemed unable to comply with study and/or follow-up procedures\n* Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Cornelius A. Thiels, D.O., M.B.A.",
                    "affiliation": "Mayo Clinic in Rochester",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic in Rochester",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials Referral Office",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "mayocliniccancerstudies@mayo.edu"
                        },
                        {
                            "name": "Travis S. Fisher",
                            "role": "CONTACT",
                            "phone": "507-538-4110",
                            "email": "Fisher.Travis1@mayo.edu"
                        },
                        {
                            "name": "Cornelius A. Thiels, D.O., M.B.A.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Travis E. Grotz, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010190",
                    "term": "Pancreatic Neoplasms"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000010182",
                    "term": "Pancreatic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2454",
                    "name": "Hyperthermia",
                    "relevance": "LOW"
                },
                {
                    "id": "M8464",
                    "name": "Fever",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13102",
                    "name": "Pancreatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000068196",
                    "term": "Albumin-Bound Paclitaxel"
                },
                {
                    "id": "D000002945",
                    "term": "Cisplatin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "asFound": "Palsy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11903",
                    "name": "Mitomycins",
                    "relevance": "LOW"
                },
                {
                    "id": "M19053",
                    "name": "Mitomycin",
                    "relevance": "LOW"
                },
                {
                    "id": "M6182",
                    "name": "Cisplatin",
                    "asFound": "Parkinson's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}